HORIZON-HLTH-2021-TOOL-06-02
HORIZON-HLTH-2021-TOOL-06-02
Programme: Horizon Europe
9 projects · €59,016,622 total EU contribution (project-level) · 80 participating organizations · 22 countries with participants
Total EU funding
Sum of EC max contribution fields for distinct projects in this topic.
€59,016,622
Countries active
Participant organizations by country (headquarters in CORDIS).
- Germany (15)
- IL (7)
- France (6)
- IE (6)
- BE (5)
- Spain (5)
- CH (4)
- Italy (4)
- Netherlands (4)
- PT (4)
- AT (3)
- UK (3)
- DK (2)
- EL (2)
- PL (2)
- SE (2)
- FI (1)
- HR (1)
- HU (1)
- IS (1)
- NO (1)
- US (1)
Open calls
From the EU Funding & Tenders Portal, linked to this topic code when it matches the call identifier. Sync via yarn etl:funding.
No open or forthcoming calls linked to this topic in the database yet.
Top organizations
By number of distinct projects in this topic.
- INSERM3 projects · FR
- ASTRAZENECA AB2 projects · SE
- BIU2 projects · IL
- EATRIS2 projects · NL
- ETH Zürich2 projects · CH
- I3S - INSTITUTO DE INVESTIGACAO E INOVACAO EM SAUDE DA UNIVERSIDADE DO PORTO2 projects · PT
- UOXF2 projects · UK
- THE HEBREW UNIVERSITY OF JERUSALEM2 projects · IL
- UKLFR2 projects · DE
- UMC UTRECHT2 projects · NL
- AU1 projects · DK
- Leiden University Medical Center1 projects · NL
Projects
Page 1 of 1
| Project | Programme | EU contribution | Total cost | |
|---|---|---|---|---|
RNA PROCESSING FOR ANTI-CANCER IMMUNOTHERAPY CANCERNA · 101057250 | HORIZON | €5,999,381 | €293,826 | Details |
A game changer for the treatment of osteoarthritis: a cost effective combined advanced therapy to treat knee osteoarthritis SINPAIN · 101057778 | HORIZON | €5,387,557 | €714,750 | Details |
Cardiac regeneration by mRNA-triggered proliferation of cardiomyocytes REGeRNA · 101057318 | HORIZON | €5,010,638 | €1,104,375 | Details |
Oral delivery of encapsulated RNA nanotherapeutics for targeted treatment of ileal Crohn's disease GENEGUT · 101057491 | HORIZON | €4,601,215 | €299,203 | Details |
Developing novel inhaled bioengineered Extracellular Vesicle RNA based advanced therapeutics, delivered by tailored aerosol delivery technology for the treatment of lung cancer INSPIRE · 101057777 | HORIZON | €13,268,023 | €5,143,561 | Details |
Gene-edited T cells combating IgA Nephropathy. A blueprint approach for safe & efficient genome editing of T cells to sustainably combat several immune diseases and cancers related to B-cell pathology geneTIGA · 101057438 | HORIZON | €6,393,734 | €1,000,313 | Details |
HLA-homozygous iPSC-cardiomyocytE Aggregate manufacturing technoLogies for allogenic cell therapy to the heart HEAL · 101056712 | HORIZON | €5,824,074 | €277,928 | Details |
Assessing efficacy and safety of genome EDITing approaches for Sickle Cell Disease EDITSCD · 101057659 | HORIZON | €6,532,000 | €1,529,500 | Details |
Next generation advanced RNA inhibition therapy to treat cardiometabolic disease LiverTarget · 101057724 | HORIZON | €6,000,000 | €650,000 | Details |